Change Language

Select Language

Global HIV Drugs Market to Reach US$ 38.9 Billion by 2027, Impelled by Rising Prevalence of AIDS

Published on Jul 14, 2022

According to the latest report by IMARC Group, titled "HIV Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027," the global HIV drugs market reached a value of US$ 29.2 Billion in 2021. Human immunodeficiency virus (HIV) is a life-threatening virus that weakens the immune system by destroying the cells that aid the human body to fight against infections. It is generally spread through unprotected sexual contact or blood transmission via injection drugs. Even though there is no effective treatment available for HIV currently, it can be controlled through prescribed medications. Apart from this, the widespread awareness regarding antiretroviral therapy (ART), which is a combination of various medicines that help in reducing the rate of virus growth in the body and monitoring white blood cells to determine the effect of the virus on the immune system, is contributing to the market growth.   

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Global HIV Drugs Market Trends:? 

The global market is primarily driven by the increasing prevalence of acquired immunodeficiency syndrome (AIDS) among the masses. Along with this, the rising awareness among individuals regarding the treatments available for AIDS has propelled the product demand. Moreover, the rising initiatives undertaken by the government and non-government organizations (NGOs) for promoting awareness programs across the globe are creating a positive market outlook. Additionally, the increasing spending by public and private agencies on extensive research and development (R&D) activities, along with the rising clinical trials and product launches, are providing a boost to the market. In line with this, continuous technological advancements in drug manufacturing processes are impacting the market further. Furthermore, the proliferation of online pharmacies and the advent of home delivery models are offering lucrative growth opportunities for major market players. Other factors, including rapid urbanization, continuous improvements in the healthcare infrastructure, and the increasing number of research laboratories and diagnostic centers, are also positively influencing the market. On account of the aforementioned factors,?the market is anticipated to reach a value of US$ 38.9 Billion by 2027, exhibiting a CAGR of 3.7% during 2022-2027.? 

Market Summary: 

  • Based on the drug class, the market has been classified into nucleoside reverse transcriptase inhibitors, multi-class combination products, protease inhibitors, HIV integrase strand transfer inhibitors, non-nucleoside reverse transcriptase inhibitors, entry inhibitors — CCR5 co-receptor antagonist, and fusion inhibitors and others.
  • On the basis of the distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, online pharmacies and others. Presently, hospital pharmacies account for the largest market share.
  • Based on the region, the market has been divided into North America, Europe, Asia Pacific, the Middle East and Africa and Latin America. Among these, North America holds the leading position in the market.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.?Some of these players include Boehringer Ingelheim International GmbH, Merck & Co., Inc., ViiV Healthcare, AbbVie, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Gilead Sciences, Inc., Johnson & Johnson, Cipla Limited, Daiichi Sankyo, Emcure, Hetero Drugs, and Mylan.


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY 82801, USA
Website: https://www.imarcgroup.com/
Email: sales@imarcgroup.com
Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800

REACH OUT TO US

Call us on

( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91-120-433-0800 )


Drop us an email at

sales@imarcgroup.com